BlackRock’s Stemline Therapeutics, Inc. STML Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-3,739,336
| Closed | -$18.1M | – | 5205 |
|
|
2020
Q1 | $18.1M | Buy |
3,739,336
+23,688
| +0.6% | +$154K | ﹤0.01% | 2657 |
|
|
2019
Q4 | $39.5M | Buy |
3,715,648
+229,235
| +7% | +$2.28M | ﹤0.01% | 2510 |
|
|
2019
Q3 | $36.3M | Buy |
3,486,413
+333,601
| +11% | +$4.36M | ﹤0.01% | 2477 |
|
|
2019
Q2 | $48.3M | Buy |
3,152,812
+449,323
| +17% | +$6.5M | ﹤0.01% | 2335 |
|
|
2019
Q1 | $34.7M | Buy |
2,703,489
+638,250
| +31% | +$7.22M | ﹤0.01% | 2487 |
|
|
2018
Q4 | $19.6M | Buy |
2,065,239
+95,747
| +5% | +$1.24M | ﹤0.01% | 2728 |
|
|
2018
Q3 | $32.7M | Buy |
1,969,492
+116,672
| +6% | +$1.87M | ﹤0.01% | 2605 |
|
|
2018
Q2 | $29.7M | Buy |
1,852,820
+281,394
| +18% | +$5.02M | ﹤0.01% | 2640 |
|
|
2018
Q1 | $24M | Buy |
1,571,426
+165,245
| +12% | +$2.58M | ﹤0.01% | 2660 |
|
|
2017
Q4 | $21.9M | Buy |
1,406,181
+83,044
| +6% | +$1.11M | ﹤0.01% | 2729 |
|
|
2017
Q3 | $14.7M | Buy |
1,323,137
+5,211
| +0.4% | +$49K | ﹤0.01% | 2959 |
|
|
2017
Q2 | $12.1M | Buy |
1,317,926
+103,033
| +8% | +$859K | ﹤0.01% | 3060 |
|
|
2017
Q1 | $10.4M | Buy |
1,214,893
+1,211,309
| +33,798% | +$11M | ﹤0.01% | 3089 |
|
|
2016
Q4 | $38K | Sell |
3,584
-346
| -9% | -$4.18K | ﹤0.01% | 3058 |
|
|
2016
Q3 | $42K | Hold |
3,930
| – | – | ﹤0.01% | 3052 |
|
|
2016
Q2 | $26K | Buy |
3,930
+3,400
| +642% | +$21.5K | ﹤0.01% | 3198 |
|
|
2016
Q1 | $3K | Buy |
530
+208
| +65% | +$1.02K | ﹤0.01% | 3432 |
|
|
2015
Q4 | $2K | Hold |
322
| – | – | ﹤0.01% | 3347 |
|
|
2015
Q3 | $3K | Hold |
322
| – | – | ﹤0.01% | 3137 |
|
|
2015
Q2 | $4K | Sell |
322
-91
| -22% | -$1.26K | ﹤0.01% | 3174 |
|
|
2015
Q1 | $6K | Buy |
+413
| New | +$6.32K | ﹤0.01% | 2997 |
|
|
2014
Q2 | – | Sell |
-340
| Closed | -$7K | – | 3260 |
|
|
2014
Q1 | $7K | Buy |
340
+76
| +29% | +$1.84K | ﹤0.01% | 2958 |
|
|
2013
Q4 | $5K | Hold |
264
| – | – | ﹤0.01% | 3059 |
|
|
2013
Q3 | $12K | Hold |
264
| – | – | ﹤0.01% | 2552 |
|
|
2013
Q2 | $6K | Buy |
+264
| New | +$4.2K | ﹤0.01% | 2984 |
|
BlackRock's STML Position: Q2 2020 in Review
BlackRock sold out of Stemline Therapeutics, Inc. (STML) in Q2 2020, closing a stake of 3,739,336 shares — an estimated $18.1M sold.
BlackRock first reported a position in STML in Q2 2013 and held it in 25 quarters. The position peaked at $48.3M in Q2 2019. 0 funds tracked by Wall St. Rank hold STML as of Q2 2020.
- BlackRock reported no remaining Stemline Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
- BlackRock sold 3,739,336 Stemline Therapeutics, Inc. shares in Q2 2020, an estimated $18.1M.
- BlackRock first reported a position in Stemline Therapeutics, Inc. in Q2 2013 and held it in 25 quarters.
- BlackRock's Stemline Therapeutics, Inc. position peaked at $48.3M in Q2 2019.
- 0 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2020.
Based on BlackRock's 13F filing for Q2 2020, filed 14 Aug 2020.